Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 9.1
edited by manuelmenendez
on 2025/01/27 23:23
on 2025/01/27 23:23
Change comment:
There is no comment for this version
To version 6.1
edited by manuelmenendez
on 2025/01/27 23:21
on 2025/01/27 23:21
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,7 +2,8 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= //A new tridimensional diagnostic framework for CNS conditions// = 5 += **Neurodiagnoses** 6 +//A new tridimensional diagnostic framework for CNS conditions// = 6 6 7 7 This project is focused on developing a novel nosological and diagnostic framework for neurological diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 8 We aim to create a structured, interpretable, and scalable diagnostic tool. ... ... @@ -15,7 +15,7 @@ 15 15 ((( 16 16 = What is this about and what can I find here? = 17 17 18 -== **Overview** == 19 +==== **Overview** ==== 19 19 20 20 The //Tridimensional Diagnostic Framework// redefines how neurodegenerative diseases (NDDs) are classified by focusing on: 21 21 ... ... @@ -29,7 +29,7 @@ 29 29 * Integration of incomplete datasets using AI-driven probabilistic modeling. 30 30 * Stratification of patients for personalized treatment. 31 31 32 -== **Diagnostic Axes** == 33 +==== **Diagnostic Axes** ==== 33 33 34 34 * ((( 35 35 **Axis 1: Etiology** ... ... @@ -53,11 +53,28 @@ 53 53 * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. 54 54 ))) 55 55 56 -== ** Applications** ==57 +==== **Case Studies** ==== 57 57 59 +1. ((( 60 +**Sporadic Alzheimer’s Disease**: 61 + 62 +* Axis 1: Sporadic (ApoE4, poor sleep habits). 63 +* Axis 2: Amyloid-beta plaques, elevated NFL. 64 +* Axis 3: Right hippocampus atrophy (visual memory loss). 65 +))) 66 +1. ((( 67 +**Genetic Parkinson’s Disease**: 68 + 69 +* Axis 1: Genetic (LRRK2 mutation). 70 +* Axis 2: Alpha-synuclein aggregation. 71 +* Axis 3: Substantia nigra degeneration (motor dysfunction). 72 +))) 73 + 74 +==== **Applications** ==== 75 + 58 58 This system enhances: 59 59 60 -* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials. 78 +* **Research**: By stratifying patients, it reduces cohort heterogeneity in clinical trials. 61 61 * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. 62 62 63 63 == Who has access? ==